BIOMAT Database Logo BIOMAT Database Logo

CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study. 1990

K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Servizio Oncologica Ticinese, Ospedale San Giovanni, Bellinzona, Switzerland.

Forty-six postmenopausal women with either locally advanced or metastatic breast cancer were treated with the aromatase inhibitor CGS 16949A in three different daily doses (0.3 mg, 0.6 mg and 0.9 mg total daily dose). 41 patients (89%) were pretreated by endocrine treatment for metastatic disease; 30 of these 41 were also pretreated with chemotherapy. Of the remaining 5 patients (11%) 3 were previously treated with chemotherapy alone and 2 were not pretreated. Evaluable sites of disease were: skin and soft tissue (including local recurrence) in 34, bone in 31, lung in 14 and viscera in 13 instances, respectively. 1 PR (3%) and 9 stable diseases (24%) were observed in the 37 patients assessable for response. All but two of these results were observed in the 0.9 mg group. Time to progression was 14 months for the patient showing a PR, and the median time to progression for those with stable disease was 6 months (range 6 to 23 months). Plasma estradiol and estrone levels were measured in patients receiving the daily dose of 0.6 mg (n = 4) and 0.9 mg (n = 15). The estrone levels decreased from a mean of 23.1 pg/mL (SD 17.1) to 10.5 pg/mL (SD 6.6) in the 0.6 mg-group and from 21.2 pg/mL (SD 18.9) to 9.1 pg/mL (SD 5.5) in the 0.9 mg-group within 4 days of drug administration (p less than 0.0001 from baseline in both groups, with no significant difference between doses).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009570 Nitriles Organic compounds containing the -CN radical. The concept is distinguished from CYANIDES, which denotes inorganic salts of HYDROGEN CYANIDE. Nitrile
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D004970 Estrone An aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone, a major mammalian estrogen. It is converted from ANDROSTENEDIONE directly, or from TESTOSTERONE via ESTRADIOL. In humans, it is produced primarily by the cyclic ovaries, PLACENTA, and the ADIPOSE TISSUE of men and postmenopausal women. Folliculin (Hormone),Estrone, (+-)-Isomer,Estrone, (8 alpha)-Isomer,Estrone, (9 beta)-Isomer,Estrovarin,Kestrone,Unigen,Wehgen
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
A phase I trial of CGS 16949A. A new aromatase inhibitor.
March 1990, Cancer,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
March 1990, Cancer research,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
April 1995, Cancer,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
May 1990, Clinical endocrinology,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
January 1990, Acta oncologica (Stockholm, Sweden),
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Potency and specificity of CGS-16949A as an aromatase inhibitor.
January 1990, Endocrine research,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma.
January 1999, Cancer,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis.
April 1990, The Journal of clinical endocrinology and metabolism,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
January 1993, Cancer research,
K R Beretta, and K Hoeffken, and S Kvinnsland, and P Trunet, and H A Chaudri, and A S Bhatnagar, and A Goldhirsch, and F Cavalli
CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
February 1988, Cancer research,
Copied contents to your clipboard!